1 | 10-mg dose of E5501 2G tablet | - | - | - | - | 1件: 63 63 |
2 | 10-mg dose of E5501 cyclodextrin oral solution | - | - | - | - | 1件: 63 63 |
3 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | 1件: 63 63 |
4 | 10-mg dose of E5501-P21% powder | - | - | - | - | 1件: 63 63 |
5 | Acetominofene | - | - | - | - | 2件: 11 11, 63 |
6 | Acetominophen | - | - | - | - | 1件: 63 63 |
7 | AKR-501, YM-477 | - | - | - | - | 1件: 63 63 |
8 | ALEMTUZUMAB | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 17件: 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 |
9 | Alemtuzumab, Rituximab | 2件: Alemtuzumab Alemtuzumab, Rituximab | 2件: D02802
D02802
,
D02994
| 2件: CD52 CD52, MS4A1 💬 | 2件: , Hematopoietic cell lineage 💬 | 1件: 63 63 |
10 | All-Trans Retinoid Acid(ATRA) | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
| 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 63 63 |
11 | AMG 531 | - | - | - | - | 1件: 63 63 |
12 | AMG531 | - | - | - | - | 2件: 60 60, 63 |
13 | Aminophylline | 1件: Aminophylline Aminophylline | 2件: D00227
D00227
,
D05429
| 18件: ADORA1 ADORA1, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 | 23件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 63 63 |
14 | Amoxicillin | 1件: Amoxicillin Amoxicillin | 3件: D00229
D00229
,
D02925
,
D07452
| - | - | 7件: 6 6, 46, 63, 96, 97, 222, 299 |
15 | Amoxicillin hydrate | 1件: Amoxicillin Amoxicillin | 3件: D00229
D00229
,
D02925
,
D07452
| - | - | 1件: 63 63 |
16 | Amoxycillin | 1件: Amoxicillin Amoxicillin | 3件: D00229
D00229
,
D02925
,
D07452
| - | - | 1件: 63 63 |
17 | Anti-CD40L | 1件: Toralizumab Toralizumab | 1件: D06193
D06193
| 1件: CD40LG CD40LG 💬 | 14件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis 💬 | 1件: 63 63 |
18 | Anti-CD40LdAb | - | - | - | - | 1件: 63 63 |
19 | Anti-D | - | - | - | - | 1件: 63 63 |
20 | ARGX-113 | - | - | - | - | 4件: 11 11, 14, 35, 63 |
21 | Atorvastatin | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 18件: 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299 |
22 | Atorvastatin 10mg | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 |
23 | Atorvastatin 20mg | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 |
24 | ATRA | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
| 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 2件: 63 63, 94 |
25 | Avatrombopag | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 2件: 60 60, 63 |
26 | Avatrombopag (proposed) | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
27 | AVATROMBOPAG MALEATE | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
28 | Avatrombopag tablets | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
29 | Azathioprine | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
30 | Blinded (Avatrombopoag tablets) | - | - | - | - | 1件: 63 63 |
31 | Blisibimod | 1件: Blisibimod Blisibimod | 1件: D10311
D10311
| - | - | 5件: 43 43, 44, 49, 63, 66 |
32 | BMS-986004 | - | - | - | - | 1件: 63 63 |
33 | BMS-986004 1500 mg IV | - | - | - | - | 1件: 63 63 |
34 | BMS-986004 225 mg IV | - | - | - | - | 1件: 63 63 |
35 | BMS-986004 675 mg IV | - | - | - | - | 1件: 63 63 |
36 | BMS-986004 75 mg IV | - | - | - | - | 1件: 63 63 |
37 | BORTEZOMIB | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 16件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 |
38 | BT595 | - | - | - | - | 2件: 63 63, 65 |
39 | Caffeic acid tablets | - | - | - | - | 1件: 63 63 |
40 | Clarithromycin | 1件: Clarithromycin Clarithromycin | 1件: D00276
D00276
| - | - | 8件: 6 6, 63, 84, 96, 97, 222, 228, 299 |
41 | Conventional | - | - | - | - | 1件: 63 63 |
42 | Corticosteroids (Aprednislon) | - | - | - | - | 1件: 63 63 |
43 | CsA | - | - | - | - | 8件: 19 19, 49, 50, 53, 60, 63, 222, 228 |
44 | Cyclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 17件: 38 38, 46, 49, 50, 53, 56, 60, 62, 63, 93, 95, 97, 113, 164, 222, 274, 326 |
45 | Cyclosporin A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 46 46, 49, 53, 56, 60, 62, 63, 93, 95, 113, 164 |
46 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
47 | Danazol | 1件: Danazol Danazol | 1件: D00289
D00289
| 3件: AR AR, ESR1, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 5件: 60 60, 63, 64, 65, 285 |
48 | Daratumumab | 1件: Daratumumab Daratumumab | 1件: D10777
D10777
| 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 5件: 16 16, 28, 49, 63, 222 |
49 | Decitabine | 1件: Decitabine Decitabine | 1件: D03665
D03665
| 3件: DNMT1 DNMT1, DNMT3A, DNMT3B 💬 | 3件: Cysteine and methionine metabolism Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer 💬 | 2件: 60 60, 63 |
50 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 25件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
51 | Dexamethasone (1 cycle) | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 |
52 | Dexamethasone (4 cycles) | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 |
53 | Dexamethasone Abcur | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 |
54 | Dexamethasone and Rituximab | 2件: Dexamethasone Dexamethasone, Rituximab | 10件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D02994
| 2件: MS4A1 MS4A1, NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 |
55 | DIACEREIN | 1件: Diacerein Diacerein | 1件: D07270
D07270
| - | - | 3件: 36 36, 46, 63 |
56 | Diammonium glycyrrhizinate enteric-coated capsule | - | - | - | - | 1件: 63 63 |
57 | Difenidramina | - | - | - | - | 2件: 11 11, 63 |
58 | DIFENIDRAMINA CLORIDRATO | - | - | - | - | 2件: 11 11, 63 |
59 | Doptelet | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
60 | Doptelet 20 mg film-coated tablets | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
61 | Doxil | - | - | - | - | 1件: 63 63 |
62 | Dyphenhydramine hydrochloride | - | - | - | - | 1件: 63 63 |
63 | E5501 | - | - | - | - | 1件: 63 63 |
64 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 |
65 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 |
66 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 |
67 | Efgartigimod | - | - | - | - | 3件: 11 11, 35, 63 |
68 | EFGARTIGIMOD ALFA | 1件: Efgartigimod alfa Efgartigimod alfa | 1件: D11876
D11876
| 1件: FCGRT FCGRT 💬 | - | 4件: 11 11, 14, 35, 63 |
69 | Efgartigimod alpha | - | - | - | - | 1件: 63 63 |
70 | Efgartigimod PH20 SC | - | - | - | - | 4件: 11 11, 14, 35, 63 |
71 | ELTROMBOPAG | 1件: Eltrombopag Eltrombopag | - | - | - | 5件: 60 60, 63, 65, 284, 285 |
72 | Eltrombopag (Revolade) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
73 | Eltrombopag (Revolade®) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
74 | Eltrombopag combining rituximab | 2件: Eltrombopag Eltrombopag, Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 63 63 |
75 | ELTROMBOPAG OLAMINE | 1件: Eltrombopag Eltrombopag | - | - | - | 2件: 60 60, 63 |
76 | Eltrombopag olamine (SB-497115-GR) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
77 | Eltrombopag olamine, Revolade, Promacta | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
78 | Eltrombopag oral tablets | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
79 | Eltrombopag plus diacerein | 2件: Diacerein Diacerein, Eltrombopag | 1件: D07270
D07270
| - | - | 1件: 63 63 |
80 | FCM | - | - | - | - | 2件: 63 63, 222 |
81 | Gammaplex | - | - | - | - | 2件: 63 63, 65 |
82 | Gammaplex, intravenous immunoglobulin | - | - | - | - | 1件: 63 63 |
83 | Glycyrrhetinic Acid | - | - | - | - | 1件: 63 63 |
84 | GMA161 | - | - | - | - | 1件: 63 63 |
85 | GNR-069 | - | - | - | - | 1件: 63 63 |
86 | HBM9161 Dose A | - | - | - | - | 1件: 63 63 |
87 | HBM9161 Dose B | - | - | - | - | 1件: 63 63 |
88 | Hetrombopag | 1件: Hetrombopag Hetrombopag | - | - | - | 2件: 60 60, 63 |
89 | Hetrombopag Olamine | 1件: Hetrombopag Hetrombopag | - | - | - | 2件: 60 60, 63 |
90 | High dose Dexamethasone pulses | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 |
91 | HMPL-523 | - | - | - | - | 2件: 46 46, 63 |
92 | Huaiqihuang Granule | - | - | - | - | 1件: 63 63 |
93 | Human Immunoglobulin | - | - | - | - | 2件: 63 63, 65 |
94 | HUMAN IMMUNOGLOBULIN G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 63, 65 |
95 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
96 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 |
97 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 |
98 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 |
99 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 |
100 | HUMAX-CD38 | - | - | - | - | 2件: 28 28, 63 |
101 | Hydroxychloroquine | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: D08050
D08050
| - | - | 27件: 13 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 |
102 | I10E | - | - | - | - | 3件: 14 14, 63, 65 |
103 | Ig VENA | - | - | - | - | 2件: 50 50, 63 |
104 | Ig VENA 100 ml vial | - | - | - | - | 1件: 63 63 |
105 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 |
106 | IgG Next Generation | - | - | - | - | 2件: 63 63, 65 |
107 | IGIV3I Grifols 10% | - | - | - | - | 1件: 63 63 |
108 | IgNextGen 10% | - | - | - | - | 1件: 63 63 |
109 | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution | - | - | - | - | 1件: 63 63 |
110 | Immunglobulin | - | - | - | - | 1件: 63 63 |
111 | Immunoglobulin | - | - | - | - | 3件: 13 13, 14, 63 |
112 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 |
113 | Inactivated Trivalent Influenza vaccine | - | - | - | - | 1件: 63 63 |
114 | INTERLEUKIN 2 | - | - | - | - | 9件: 46 46, 49, 51, 56, 63, 95, 96, 97, 271 |
115 | IVIG-L | - | - | - | - | 1件: 63 63 |
116 | Lansoprazole | 1件: Lansoprazole Lansoprazole | 1件: D00355
D00355
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 7件: 63 63, 71, 85, 98, 166, 222, 299 |
117 | Lansoprazole, clarithromycin, amoxycillin | 3件: Amoxicillin Amoxicillin, Clarithromycin, Lansoprazole | 5件: D00229
D00229
,
D00276
,
D00355
,
D02925
,
D07452
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 63 63 |
118 | LIV-GAMMA SN Inj. | - | - | - | - | 1件: 63 63 |
119 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
120 | Medical Standard of Care for ITP | - | - | - | - | 1件: 63 63 |
121 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
122 | METILPREDNISOLONE | - | - | - | - | 6件: 11 11, 13, 53, 56, 63, 300 |
123 | METRONIDAZOLE | 1件: Metronidazole Metronidazole | 3件: D00409
D00409
,
D05016
,
D05017
| - | - | 8件: 46 46, 51, 63, 94, 95, 96, 97, 291 |
124 | Montelukast | 1件: Montelukast Montelukast | 2件: D00529
D00529
,
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
125 | Nanogam | - | - | - | - | 1件: 63 63 |
126 | NewGam | - | - | - | - | 3件: 14 14, 63, 65 |
127 | NPLATE | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
128 | NPLATE 500 microgramos polvo para solución inyectable | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
129 | Null | - | - | - | - | 16件: 6 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
130 | Octagam 10% | - | - | - | - | 3件: 50 50, 63, 65 |
131 | Octagam® 10% | - | - | - | - | 1件: 63 63 |
132 | Open Label (Avatrombopag tablets) | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
133 | Orelabrutinib | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 13 13, 61, 63 |
134 | Orelabrutinib( higher dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 |
135 | Orelabrutinib( lower dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 |
136 | Other: healthy controls | - | - | - | - | 1件: 63 63 |
137 | Other: RP% Measurement by FCM as a Diagnostic Test for ITP | - | - | - | - | 1件: 63 63 |
138 | Palmitate | 1件: Palmitic Acid Palmitic Acid | 1件: D05341
D05341
| - | - | 1件: 63 63 |
139 | PARACETAMOLO | - | - | - | - | 8件: 2 2, 11, 14, 28, 53, 61, 63, 300 |
140 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 |
141 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 |
142 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 |
143 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 |
144 | PG2 | - | - | - | - | 1件: 63 63 |
145 | Placebo | - | - | - | - | 27件: 3 3, 5, 6, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
146 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 43件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
147 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
148 | Privigen® | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 |
149 | Promacta | 1件: Eltrombopag Eltrombopag | - | - | - | 2件: 63 63, 65 |
150 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | 1件: 63 63 |
151 | PRTX-100 (Staphylococcal protein A) | 1件: Bevifimod Bevifimod | - | - | - | 1件: 63 63 |
152 | R788 | - | - | - | - | 2件: 46 46, 63 |
153 | Recombinant Human Thrombopoietin | 2件: Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | 1件: 63 63 |
154 | Recombinant human thrombopoietin (rh-TPO) | 2件: Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | 1件: 63 63 |
155 | Recombinant Human Thrombopoietin (rhTPO) | 2件: Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Thrombopoietin | - | - | - | 1件: 63 63 |
156 | Relovade | - | - | - | - | 1件: 63 63 |
157 | REVOLADE | 1件: Eltrombopag Eltrombopag | - | - | - | 2件: 60 60, 63 |
158 | Revolade 25 mg film-coated tablets | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
159 | Revolade 50 mg film-coated tablets | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
160 | REVOLADE, PROMACTA | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
161 | RhTPO | 1件: Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin | - | - | - | 2件: 60 60, 63 |
162 | RhTPO in combination with Rituximab | 2件: Recombinant Human Thrombopoietin Recombinant Human Thrombopoietin, Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 63 63 |
163 | Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
164 | Rituximab [MabThera/Rituxan] | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 46 46, 63 |
165 | Romiplostim | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 4件: 60 60, 63, 64, 65 |
166 | Romiplostin | - | - | - | - | 1件: 63 63 |
167 | ROZANOLIXIZUMAB | 1件: Rozanolixizumab Rozanolixizumab | 1件: D12182
D12182
| 1件: FCGRT FCGRT 💬 | - | 3件: 11 11, 14, 63 |
168 | SB-497115 | - | - | - | - | 1件: 63 63 |
169 | SB-497115-GR | - | - | - | - | 1件: 63 63 |
170 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 |
171 | SB-497115-GR 25mg | - | - | - | - | 1件: 63 63 |
172 | SB-497115-GR 50 mg | - | - | - | - | 1件: 63 63 |
173 | SB497115 | - | - | - | - | 2件: 60 60, 63 |
174 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 36件: 6 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
175 | SM101 | - | - | - | - | 3件: 49 49, 63, 66 |
176 | SM101 20mg/mL | - | - | - | - | 1件: 63 63 |
177 | SM101 5mg/mL | - | - | - | - | 1件: 63 63 |
178 | Standard of Care | - | - | - | - | 10件: 6 6, 13, 46, 49, 51, 63, 64, 79, 171, 271 |
179 | Standard therapy (without eltrombopag): HD-DXM | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 |
180 | STAPHYLOCOCCAL PROTEIN A | 1件: Bevifimod Bevifimod | - | - | - | 1件: 63 63 |
181 | Steroids | - | - | - | - | 7件: 46 46, 50, 51, 63, 66, 96, 97 |
182 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 |
183 | Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication) | 3件: Amoxicillin Amoxicillin, Clarithromycin, Metronidazole | 7件: D00229
D00229
,
D00276
,
D00409
,
D02925
,
D05016
,
D05017
,
D07452
| - | - | 1件: 63 63 |
184 | Thrombopoietin | 1件: Thrombopoietin Thrombopoietin | - | - | - | 3件: 47 47, 60, 63 |
185 | TPO | - | - | - | - | 1件: 63 63 |
186 | Triple therapy | - | - | - | - | 1件: 63 63 |
187 | TYSABRI | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 3件: 13 13, 25, 63 |
188 | UCB7665 | - | - | - | - | 3件: 11 11, 14, 63 |
189 | Vonoprazan | 1件: Vonoprazan Vonoprazan | 1件: D11784
D11784
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 63 63, 98 |
190 | Water | 1件: Water Water | 1件: D00001
D00001
| - | - | 23件: 2 2, 5, 6, 13, 17, 19, 22, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 |